Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Incyte
Incyte
Opportunities arise for once-spurned partners
EP Vantage
Fri, 05/13/22 - 10:34 am
Pfizer
Biohaven
licensing
M&A
Aurinia
Bristol Myers Squibb
AbbVie
Alector
Arcus Biosciences
Biogen
Blueprint Medicines
CureVac
Gilead Sciences
GSK
Incyte
MorphoSys
Roche
Nestle
SAGE Therapeutics
Sarepta Therapeutics
Seres Therapeutics
Syndax
FDA approves new indication for drug to treat severe COVID-19
Beckers Hospital Review
Thu, 05/12/22 - 10:51 pm
Eli Lilly
Incyte
baricitinib
FDA
olumiant
COVID-19
Incyte's Opzelura slapped with vitiligo delay amid topical JAK's eczema launch
Fierce Pharma
Mon, 03/14/22 - 11:37 pm
Incyte
Opzelura
eczema
vitiligo
A new JAK inhibitor earns FDA nod in myelofibrosis, setting up a fight with Incyte, Bristol Myers
Endpoints
Tue, 03/1/22 - 10:35 am
CTI BioPharma
JAK inhibitors
Vonjo
pacritinib
FDA
myelofibrosis
Incyte
Bristol Myers Squibb
Novartis JAKs in rival to Incyte's topical eczema drug after seeing clinical data
Fierce Biotech
Wed, 02/2/22 - 10:59 am
Novartis
Incyte
JAK inhibitors
Opzelua
eczema
atopic dermatitis
Eli Lilly, Incyte axe Olumiant in lupus amid eczema stalemate at FDA
Fierce Pharma
Fri, 01/28/22 - 11:47 am
Eli Lilly
Incyte
olumiant
FDA
lupus
eczema
Incyte pulls FDA filing for cancer drug approval over confirmatory study, following Gilead out of the exit
Fierce Biotech
Wed, 01/26/22 - 10:57 am
Incyte
FDA
parsaclisib
FDA sets April date for verdict on Incyte’s vitiligo drug
Pharmaforum
Wed, 12/15/21 - 10:43 am
Incyte
Opzelura
vitiligo
FDA
What Novartis could buy with its windfall
EP Vantage
Fri, 11/5/21 - 09:40 am
Novartis
M&A
Roche
Sandoz
Aurinia Pharmaceuticals
Alnylam
Exelixis
Incyte
Eisai
Genmab
Incyte (INCY) Q3 Earnings and Revenues Beat Estimates
Yahoo/Zacks.com
Tue, 11/2/21 - 10:49 am
Incyte
earnings
Lilly, Incyte: Olumiant Superior to Placebo in Scalp Hair Regrowth as Early as 24 Weeks
Marketwatch
Fri, 10/1/21 - 10:51 am
Lilly
Incyte
clinial trials
olumiant
alopecia areata
Incyte and Syndax to jointly develop and commercialize axatilimab
Pharmaceutical Business Review
Tue, 09/28/21 - 12:01 pm
Incyte
Syndax Pharma
axatilimab
graft vs host disease
Incyte on a Roll with Two FDA Wins in Two Days
BioSpace
Thu, 09/23/21 - 10:55 pm
Incyte
FDA
Jakafi
graft vs host disease
ruxolitinib
atopic dermatitis
Incyte nabs approval of topical ruxolitinib in atopic dermatitis, but gets slapped with JAK warning
Endpoints
Wed, 09/22/21 - 11:17 am
FDA
Incyte
atopic dermatitis
ruxolitinib
BioMarin stands tall with first approved drug for rare disease that causes dwarfism
MedCity News
Sat, 08/28/21 - 08:57 pm
Biomarin
Europe
achondroplasia
dwarfism
Incyte
MorphoSys
Lilly has a bad hair day as Pfizer rival hits the mark in alopecia
Pharmaforum
Wed, 08/4/21 - 10:50 pm
Eli Lilly
Incyte
Pfizer
alopecia areata
ritlecitinib
clinical trials
FDA unsurprisingly brings down the hammer on Incyte's PD-1 — drawing a line for future accelerated approvals
Endpoints
Mon, 07/26/21 - 09:36 am
Incyte
retifanlimab
FDA
anal cancer
No fast way to eighth place for Incyte
EP Vantage
Fri, 06/25/21 - 10:58 am
Macrogenics
Incyte
retifanlimab
monoclonal antibodies
FDA
FDA slams Incyte's PD-1 over single-arm study, low response and trial deaths
Endpoints
Wed, 06/23/21 - 11:06 am
Incyte
FDA
clinical trials
retifanlimab
Incyte hits 2nd FDA delay in span of days, this time for atopic dermatitis hopeful ruxolitinib cream
Fierce Pharma
Sat, 06/12/21 - 10:23 pm
Incyte
atopic dermatitis
ruxolitinib
FDA
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »